Novartis Acquires Breast Cancer Drug for $3 Billion, Strengthens Pipeline

Novartis acquired a breast cancer drug in a $3 billion deal, strengthening its cancer treatment portfolio. The agreement includes PI3Kα breast cancer drug SNV4818. Novartis stock climbed following the announcement.

Novartis has agreed to acquire SNV4818, a next-generation PI3Kα inhibitor targeting breast cancer mutations, from biotech Synnovation in a deal valued at up to $3 billion. The transaction includes a $2 billion upfront payment with the remainder contingent on clinical and regulatory milestones. NVS shares climbed following the announcement, reflecting investor confidence in the oncology pipeline expansion.

SNV4818 is designed as a successor to Novartis' existing breast cancer drug Piqray (alpelisib), targeting a broader range of PI3Kα mutations with an improved tolerability profile. The acquisition strengthens Novartis' position in HR+/HER2- breast cancer treatment — one of the largest and fastest-growing segments in oncology — where competition from Roche, AstraZeneca, and Eli Lilly has intensified.

The deal reflects Novartis' strategy of acquiring late-stage clinical assets that can leverage its established oncology commercialization infrastructure rather than building early-stage pipeline from scratch. With blockbuster drugs Cosentyx and Kisqali facing patent cliffs later this decade, M&A-driven pipeline reinforcement is a critical lever for sustaining NVS's revenue growth trajectory and justifying its oncology-focused valuation premium.